Hansa Biopharma AB
Hansa Biopharma AB
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Imlifidase Prior to Kidney Transplant in Highly Sensitised Children | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Phase 2 | 2026-08-18 | NCT05753930 | |
| A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group | Long Term Efficacy and Safety | Active, not recruiting | Phase 3 | 2026-06-23 | NCT05937750 | |
| Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys | Kidney Transplantation in Highly Sensitized Patients | Active, not recruiting | Not stated | 2025-11-18 | NCT05714514 | |
| Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crigler-Najjar syndrome, Nutritional and Metabolic Diseases, hereditary disease, hereditary hyperbilirubinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 2 | 2024-12-03 | NCT06518005 |